“A small but rapidly growing number of U.S. adolescents began treatment with Novo Nordisk’s weight-loss drug Wegovy last year, a powerful new tool to address record rates of pediatric obesity.
In the first 10 months of 2023, 1,268 children ages 12 to 17 with an obesity diagnosis* started taking Wegovy, according to U.S. insurance claims data compiled by health technology company Komodo Health.”
This psychological condition via framing the obesity epidemic as a “disease” with an accompanying “diagnosis” is not to be overlooked, as it provides valuable insight into how the pharmaceutical industry successfully parlays every physical, psychological, and social ailment into a medical diagnosis through a process called “medicalization” that I have previously described in great detail, which then opens the door for expensive, patented pharmaceutical interventions where they don’t naturally belong.
Strategically placing obesity within the “disease” bucket precludes the individual (referred to as “the patient,” an object to be worked upon, like a car with a faulty transmission) from exercising any personal agency over their health. Instead, the patient’s issue becomes a medical one best left to the anointed “experts” to resolve — almost always with expensive drugs or surgeries.
The actual disease, whether real or invented, obesity or “gender dysphoria,” is rarely resolved, but, given the financial incentives to keep the pill mills churning out product, one has to wonder whether that was ever the point from the industry’s perspective to begin with.
In 2022, only 25 children were prescribed the drug, which did not receive U.S. approval for adolescent use until December of that year. A month later, the influential American Academy of Pediatrics recommended weight-loss drugs be offered to children with obesity starting at age 12.”
In a decent society, the American Academy of Pediatrics would be designated a criminal enterprise, if not a biomedical terrorist organization, and its ringleaders prosecuted with vigor.
“In 2018, AAP reported $121,878,940 in revenue and $62,163,314 in net assets. More than half of its revenue came from its memberships, journals, and publications. The AAP also reported receiving $20.5 million in government grants and over $12.9 million in outside contributions. That same year, AAP reported $118,478,392 in expenses, including nearly $800,000 spent on legislative lobbying.
AAP gains a significant portion of its revenue through sponsorships at its conferences and frequent member events, though it has received criticism for its seemingly hypocritical sponsorship arrangements. In 2010, AAP hosted a conference which featured SweetSurprise.com, a corn-syrup promotion compony, as a sponsor, despite the fact that the AAP itself advocated against high fructose corn syrup and claimed that soda consumption was associated with higher rates of obesity.”
